Eli Lilly ( LLY 1.07%) and Novo Nordisk ( NVO -1.99%) are two of the most valuable healthcare stocks in the world, largely ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 478.78% and ...

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

As highly effective but pricey weight loss drugs gain popularity ... officials said that testing by Eli Lilly, the maker of Mounjaro and Zepbound, after the raid revealed that one of the samples ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk. Reuters Eli Lilly said Wednesday that its obesity drug Zepbound ...